series-a
Stage
1
Investors
About
Kernal develops in vivo cell therapies by delivering mRNA sequences directly to target tissues and cells to program them inside the body using AI models, enabling scalable CAR-T therapies for cancer and autoimmune diseases.
Explore Kernal's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.